Advertisement

Herd immunity is achievable, but it will be tight, Francis Collins, other AACR panelists say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In surveys, as many as 15% of Americans say that they will not get a COVID-19 vaccine under any circumstances, and another 17% are in the “wait-and-see” category, holding out to observe how others fare.

If these numbers are correct, the U.S. has almost no wiggle room as it strives to reach herd immunity to COVID-19. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Advertisement
Advertisement